High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia
- Title
- High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia
- Other Titles
- TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia
- Author
- 황승용
- Keywords
- AML; standard chemotherapy; prognosis; topoisomerase 2; TOPOISOMERASE-II-ALPHA; DEOXYCYTIDINE KINASE; DRUG-SENSITIVITY; GENE-EXPRESSION; BLAST CELLS; CYTARABINE; RESISTANCE; IDENTIFICATION; ANTHRACYCLINES; DAUNORUBICIN
- Issue Date
- 2012-08
- Publisher
- Nature Publishing Group
- Citation
- The British journal of cancer,Vol.107,No.1 [2012],p108-115
- Abstract
- BACKGROUND: Cytosine arabinoside-based chemotherapy coupled with anthracycline is currently the first-line treatment for acute myeloid leukaemia (AML), but diverse responses to the regimen constitute obstacles to successful treatment. Therefore, outcome prediction to chemotherapy at diagnosis is believed to be a critical consideration. METHODS: The mRNA expression of 12 genes closely involved in the actions of cytosine arabinoside and anthracycline was evaluated by real-time reverse transcriptase PCR (RT-PCR), in 54 diagnostic bone marrow specimens of M2-subtype AML. RESULTS: Low expression levels of ribonucleotide reductase M2 (RRM2) and high expression levels of topoisomerase 2 beta (TOP2B) were correlated with longer survival in a univariate analysis. Another interesting finding is that high ratios of TOP2B/RRM2 and TOP2B/TOP2 alpha (TOP2A) in a combined analysis were also shown to have a prognostic impact for longer survival with improved accuracy. Among the four markers, when adjusted for the influence of other clinical factors in multivariate analysis, the TOP2B/TOP2A ratio was significantly correlated with treatment outcomes; patients with high ratios trended toward longer disease-free survival (HR, 0.24; P = 0.002) and overall survival (HR, 0.29; P = 0.005). CONCLUSION: Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype. British Journal of Cancer (2012) 107, 108-115. doi: 10.1038/bjc.2012.206 www.bjcancer.com Published online 24 May 2012 (C) 2012 Cancer Research UK
- URI
- http://search.proquest.com/docview/1022287328?accountid=11283http://hdl.handle.net/20.500.11754/41380
- ISSN
- 0007-0920
- DOI
- 10.1038/bjc.2012.206
- Appears in Collections:
- GRADUATE SCHOOL[S](대학원) > BIONANOTECHNOLOGY(바이오나노학과) > Articles
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML